Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4). [VICRIVIROC in trattamento combinato con un regime ART ottimale in pazienti affetti da HIV pretrattati (VICTOR E4).]

Trial Profile

Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4). [VICRIVIROC in trattamento combinato con un regime ART ottimale in pazienti affetti da HIV pretrattati (VICTOR E4).]

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Vicriviroc (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms VICTOR-E4
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Jan 2014 Actual end date changed as reported in ClinicalTrials.gov record.
    • 15 Mar 2010 Status changed from active, no longer recruiting to completed.
    • 20 Feb 2010 Primary endpoint 'Virological response rate' has not been met; results reported at CROI 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top